ROC analysis demonstrated that a FABP4 value > 2.30 ng/ml was the exclusionary cut-off point to differentiate and rule out thalassemia-associated cardiometabolic/ adverse metaflammation cases from non-obese controls (Table 5), with 90% sensitivity and 93.3% specificity (Fig. 1). This evidence concerns the gene FABP4 and thalassemia.